Novartis Ag (NVSEF) Receivables - Net (2009 - 2025)

Novartis Ag has disclosed Receivables - Net across 14 years of filings, most recently posting $8.9 billion for Q4 2025.

• Receivables - Net for Q4 2025 came in at $8.9 billion, up 20.4% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.9 billion (up 20.4% YoY), and the FY2025 annual result was $8.9 billion, up 20.4% from the prior year.
• Receivables - Net came in at $8.9 billion for Q4 2025 at Novartis Ag, down from $9.1 billion in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $9.2 billion in Q2 2023 to a low of $7.1 billion in Q4 2023.
• The 5-year median for Receivables - Net is $8.3 billion (2021), against an average of $8.3 billion.
• Across the five-year window, Receivables - Net dropped 11.89% in 2023 and grew 20.4% in 2025, its largest moves.
• Novartis Ag's Receivables - Net stood at $8.0 billion in 2021, then grew by 0.76% to $8.1 billion in 2022, then slipped by 11.89% to $7.1 billion in 2023, then advanced by 4.45% to $7.4 billion in 2024, then increased by 20.4% to $8.9 billion in 2025.
• The last three Receivables - Net figures came in at $8.9 billion (Q4 2025), $9.1 billion (Q2 2025), and $7.4 billion (Q4 2024), per Business Quant data.